Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue Performance and Product Sales
GILD logo

Gilead Revenues Reach $7 Billion as HIV Sales Climb 10% Amidst Strategic Oncology Shift

GILD10-QFiling Date: 5/7/2026
Gilead Sciences, Inc.
Description

What this story covers

Gilead Sciences reported a 4% revenue increase to $7.0 billion in Q1 2026, driven by a 10% surge in HIV product sales. Despite declining COVID-19 related revenues, the company maintained strong liquidity and expanded gross margins to 79.2%.

Story snapshot

CompanyGilead Sciences, Inc.
TickerGILD
VariantStandard detailed
Duration12:32
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000882095-26-000024
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in